Drug Trial Radar · NCT03840616
Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections
Last checked: Nov 20, 2026Latest source record: Feb 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
219
Actual
Start
Mar 13, 2019
Primary completion
Dec 2, 2020
Study completion Dec 2, 2020
Sponsor
- Lead sponsor
- Mycovia Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute vulvovaginal candidiasis (VVC) in the past 12 months. Several properties of oteseconazole (VT-1161) suggest it might be a safer and more effective treatment of RVVC than other oral antifungal medications. This study will evaluate the effectiveness and safety of oteseconazole (VT-1161) for the treatment of acute VVC episodes in patients with RVVC and consists of 2 parts. The first part of the study is a 2-week induction phase for the treatment of the patient's current VVC episode when the patient will take either fluconazole or oteseconazole (VT-1161) according to a random assignment. The second part consists of an 11-week maintenance phase, when the patient will take either oteseconazole (VT-1161) or a placebo according to the random assignment from the first part of the study, and then a 37-week follow-up period.
Conditions
- Recurrent Vulvovaginal Candidiasis
Interventions
Oteseconazole (VT-1161) 150mg capsuleDrug
600mg administered on Day 1 and 450mg administered on Day 2, followed by 150mg administered once weekly for 11 weeks staring on Day 14.
Fluconazole 150mg capsuleDrug
150mg administered every 72 hours in 3 sequential doses starting on Day 1.
PlaceboDrug
Administered once weekly starting on Day 14.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-treat (ITT) PopulationTime frame: 48 Weeks
Locations
33 sites in 1 country. Site status is shown where the registry gives one.
34
Tucson, Arizona
39
Encino, California
25
Los Angeles, California
22
Englewood, Colorado
49
Boca Raton, Florida
14
Gainesville, Florida
13
Leesburg, Florida
33
Loxahatchee Groves, Florida
36
Miami, Florida
17
Savannah, Georgia
27
Idaho Falls, Idaho
10
Nampa, Idaho
62
Chicago, Illinois
41
Fort Wayne, Indiana
30
Marrero, Louisiana
50
Dearborn Heights, Michigan
29
Saginaw, Michigan
55
Traverse City, Michigan
32
Troy, Michigan
26
Kansas City, Missouri
42
New Brunswick, New Jersey
47
Ocean City, New Jersey
37
Charlotte, North Carolina
38
Fayetteville, North Carolina
15
Columbus, Ohio
18
Bluffton, South Carolina
48
Myrtle Beach, South Carolina
20
Bristol, Tennessee
21
Murfreesboro, Tennessee
24
Austin, Texas
23
Fort Worth, Texas
63
Katy, Texas
58
League City, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.